GB Sciences, Inc. Announces the First Fully Functional GrowBLOX(TM) Cultivation Chamber Has Arrived in the United States; Additional Units to Follow


LAS VEGAS, Aug. 4, 2014 (GLOBE NEWSWIRE) -- GrowBLOX Sciences, Inc. (OTCQB:GBLX), a medical marijuana research and development company, announced the first fully functional model of their cutting-edge GrowBLOX™ Cultivation Chamber has arrived in the United States after being assembled in China. The GrowBLOX™ has landed in Los Angeles, California, and is expected to arrive in Las Vegas, Nevada, within one or two days. Additional units will follow soon thereafter.

CEO Craig Ellins said, "This is a true milestone for our company. Years of development, science, and engineering have gone into the GrowBLOX™ technology. This technology will allow us to vertically integrate a revolutionary grow method to consistently provide patients with the highest grade of medical marijuana possible. In addition, the GrowBLOX™ will help supply us with quality cannabis for the production of a pharmaceutical product line. We are excited to bring our technology to the medical marijuana market and look forward to fueling its advancement."

Mr. Ellins plans on issuing a shareholder update later this week to include images of the GrowBLOX™ Cultivation Chamber. The Company also plans to implement a webcam inside the GrowBLOX™ Cultivation Chamber that will stream a live video on the corporate website of the actual grow process.

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc., is a research and biotechnical company that has developed proprietary indoor growing chambers specifically designed for medical cannabis cultivation. The GrowBLOX chamber allows for completely controlled growing conditions, ensuring the manufacture of a consistent, toxin-free, natural and medicinal-grade product. The Company believes that the advantages of a controlled environment over traditional outdoor or greenhouse growing, will empower the public, nutraceutical and pharmaceutical industries to embrace cannabis as an effective treatment for a myriad of serious medical conditions. http://www.gbsciences.com

Forward-Looking Statements

Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


            

Contact Data